ExThera’s proprietary Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a first-of-its kind, CE Marked, technology designed to reduce bloodborne pathogens during bloodstream infections. Validated in preclinical studies and in a clinical trial in Europe, the device promises to address significant unmet needs for immediate treatment, even before the pathogen is identified.
Seraph’s broad-spectrum ability to reduce the pathogen bioburden without harming the treated blood gives it many potential clinical applications. The company has evaluated the therapeutic use of Seraph 100 in a dialysis-like extracorporeal circuit for treating patients with both drug-resistant and drug-susceptible bloodstream infections.
Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) can be used to safely reduce the concentration of bacteria, viruses, fungi, and sepsis mediators in blood.
The Seraph 100 has broad applications for the safe reduction of drug-susceptible and drug-resistant pathogens – including the following pathogens which have been found to bind to Seraph 100 in studies by multiple independent laboratories.